D-Glutamate

D-Glutamate

SCHEMBL757896

NC(CCC(=O)[O-])C(=O)[O-].[H+].[H+]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.48
BBOX1 O75936 1/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRIK1 P39086 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIK2 Q13002 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL1897914 0.98 CA1 (0.50) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL1518007 0.98 CA1 (0.50) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL1301472 0.98 CA1 (0.46) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL1899057 0.98 CA1 (0.46) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL23611029 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL161673 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL377275 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL21638309 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL20593979 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D
D-Glutamate SCHEMBL1457846 0.95 CA1 (0.48) CA1BBOX1GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014020131-A1 ANTIMICROBIAL COMPOSITION, DEVICE COMPRISING IT AND PROCESS CRAWFORD HEALTHCARE LTD (GB) 2014-02-06 WO claimed
WO-2014020133-A2 PROCESS AND DEVICE CRAWFORD HEALTHCARE LTD (GB) 2014-02-06 WO claimed
US-20230381144-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN SYNVENTA LLC (US) 2023-11-30 US disclosed
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof Exciva GmbH (DE) 2022-10-25 US disclosed
WO-2021102330-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN SYNVENTA LLC (US) 2021-05-27 WO disclosed
US-20210155597-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN SYNVENTA LLC 2021-05-27 US disclosed
US-20200261442-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF VEPACHEDU SREENIVASARAO (US) 2020-08-20 US disclosed
EP-3618819-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF Exciva GmbH (DE) 2020-03-11 EP disclosed
US-20200069674-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF Exciva GmbH (DE) 2020-03-05 US disclosed
US-10392423-B2 Peptide-based inhibitors of MLL/SET1 family core complexes THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2019-08-27 US disclosed
WO-2018204713-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) 2018-11-08 WO disclosed
EP-2286238-A1 METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS Biocant - Associação De Transferência De Tecnologia (PT) 2011-02-23 EP disclosed
WO-2009141619-A1 METHODS OF DISTINGUISHING BETWEEN GLUTAMINE FORMED BY CATAPLEROSIS OR PROTEOLYSIS Biocant - Associação De Transferência De Tecnologia (PT) 2009-11-26 WO disclosed
CN-1215835-C Ketone derivatives and medical use thereof TORAY INDUSTRIES (JP) 2005-08-24 CN disclosed
US-20040053385-A1 Crystal structure ASTEX TECHNOLOGY LIMITED (GB) 2004-03-18 US disclosed
EP-1373482-A2 CRYSTALS OF KETOPANTOATE HYDROXYMETHYLTRANSFERASE Astex Technology Limited (GB) 2004-01-02 EP disclosed
WO-2002079460-A2 CRYSTALS OF KETOPANTOATE HYDROXYMETHYL TRANSFERASE ASTEX TECHNOLOGY LIMITED (GB) 2002-10-10 WO disclosed
US-6030625-A Bordetella pertussis and Bordetella parapertussis strains INSTITUT PASTEUR (FR) 2000-02-29 US disclosed
US-5985286-A ADENYL CYCLASE-HEMOLYSIN (AC-HLY) PROTEIN, INSTITUT PASTEUR (FR) 1999-11-16 US disclosed
EP-0443560-A2 HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1991-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11478467-B2 Targeted drug rescue with novel compositions, combinations, and methods thereof HTR2A, HTR2C, CYP3A43 CA1 2142/4885BBOX1 510/4885GRM8 1483/4885
US-20200069674-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF HTR2A, HTR2C, CYP3A43 CA1 2142/4885BBOX1 510/4885GRM8 1483/4885
US-20230381144-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN TRPV1, OPRL1, ADRA2C CA1 2203/4885BBOX1 1039/4885GRM8 859/4885
US-10392423-B2 Peptide-based inhibitors of MLL/SET1 family core complexes MLLT1, RBX1, SETDB1 CA1 1866/4885BBOX1 3102/4885GRM8 1908/4885
US-20200261442-A1 TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF HTR2C, HTR2A, HTR3A CA1 1799/4885BBOX1 783/4885GRM8 195/4885
US-20210155597-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN TRPV1, OPRL1, OPRK1 CA1 1729/4885BBOX1 1754/4885GRM8 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.